#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **SCHEDULE 13D**

#### Under the Securities Exchange Act of 1934 (Amendment No. 6)\*

## **RELMADA THERAPEUTICS, INC.**

(Name of Issuer)

#### Common Stock, \$0.001 par value per share

(Title of Class of Securities)

# 75955J 204

(CUSIP Number)

Matthew D. Eitner Chief Executive Officer Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, 5<sup>th</sup> Floor, New York, NY 10036 (212) 953-4900

Copies to:

Dennis J. Block Greenberg Traurig, LLP 200 Park Avenue New York, NY 10166 (212) 801-2222

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 22, 2015

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  $\Box$ 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 75955J 204			
1     Names of reporting persons			
Laidlaw & Company (UK) Ltd.			
2		e appropriate box if a member of a group	
	(a) 🗵	(b) 🗆	
3	SEC use	only	
4	Source of OO	t funds	
	00		
5	Check if	disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
6	Citizensh	ip or place of organization	
	England a	& Wales	
		7 Sole voting power	
		0	
		8 Shared voting power	
	nber of		
	nares	0	
	ficially by each		
	orting	9 Sole dispositive power	
	on with	0	
		10 Shared dispositive power	
		0	
11	Aggregat	e amount beneficially owned by each reporting person	
	0		
	0		
12	2. Check if the aggregate amount in Pow (11) evolutes cortain shares $\Box$		
13	Percent of	f class represented by amount in Row (11)	
	0%		
	070		
14	Type of r	renorting person	
17	14 Type of reporting person		
	BD		

CUSI	CUSIP No. 75955J 204			
1				
	Matthew D. Eitner			
	<u>C1</u> 1 1			
2	Check the appropriate box if a member of a group (a) $\boxtimes$ (b) $\square$			
	(a) 🖂	(0) 🗅		
3	SEC use	only		
4	Source of	-		
т	PF	i iunus		
5	Check if	disclos	sure of legal proceedings is required pursuant to Item $2(d)$ or $2(e) \boxtimes$	
6			lace of organization	
0	Chilzensi	np or p		
	United St	tates		
		7	Sole voting power	
			0	
		8	Shared voting power	
	nber of		1,136,605 <sup>1</sup>	
	hares eficially		1,150,005	
	d by each	9	Sole dispositive power	
rep	orting		Sole dispositive power	
pers	on with		0	
		10	Shared dispositive power	
			1	
			1,136,605 <sup>1</sup>	
11	Aggregate amount beneficially owned by each reporting person			
	1 1 2 (	6,605 <sup>1</sup>		
	1,130	5,605		
12	2 Check if the aggregate amount in Row (11) excludes certain shares □			
13				
15	reicent 0	or crass	represented by amount in Now (11)	
	9.62%	$\sqrt{2}$		
	2.027	-		
14	Type of r	eporti	ng person	
		1		
	IN			

<sup>1</sup> Includes (i) 585,233 shares of Common Stock registered in the name of Mr. Eitner (including 111,247 shares of Common Stock underlying warrants and restricted stock awards), (ii) 7,060 shares of Common Stock registered in the name of Mr. Eitner's wife, Katie L. Eitner, and (iii) 544,312 shares of Common Stock registered in the name of Mr. Ahern (including 111,246 shares of Common Stock underlying warrants and restricted stock awards).

<sup>2</sup> Calculated based on 11,592,278 shares of the Common Stock outstanding as of November 18, 2015, as reported in the Issuer's Schedule 14A filed with the SEC on November 27, 2015 ("<u>Schedule 14A</u>"), and adjusted for shares of Common Stock underlying warrants and restricted stock awards beneficially owned by Mr. Eitner and Mr. Ahern.

CUSI	CUSIP No. 75955J 204			
1				
	James P. Ahern			
2				
	(a) 🗵	(b) 🗆		
	are.	1		
3	SEC use	-		
4	Source of	f funds		
	PF			
5	Check if	disclos	sure of legal proceedings is required pursuant to Item $2(d)$ or $2(e) \boxtimes$	
6	Citizensh	ip or p	lace of organization	
	United St	tates		
		1		
		7	Sole voting power	
			0	
		8	Shared voting power	
N	nber of	0	Shared voting power	
	hares		1,136,605 <sup>3</sup>	
	eficially			
owne	d by each	9	Sole dispositive power	
	orting			
pers	on with		0	
		10	Shared dispositive power	
			1 10 4 10 3	
			1,136,605 <sup>3</sup>	
11	Aggregate amount beneficially owned by each reporting person			
	1 1 2 (	5,605 <sup>3</sup>		
	1,130	,005		
12	2 Check if the aggregate amount in Row (11) excludes certain shares □			
12				
15	reicent 0	or crass	represented by amount in Now (11)	
	9.62%	<sup>4</sup>		
	7.02/0			
14	Type of r	eporti	ng person	
	- ) - 0 011	- r Stell		
	IN			

<sup>3</sup> Includes (i) 585,233 shares of Common Stock registered in the name of Mr. Eitner (including 111,247 shares of Common Stock underlying warrants and restricted stock awards), (ii) 7,060 shares of Common Stock registered in the name of Mr. Eitner's wife, Katie L. Eitner, and (iii) 544,312 shares of Common Stock registered in the name of Mr. Ahern (including 111,246 shares of Common Stock underlying warrants and restricted stock awards).

<sup>4</sup> Calculated based on 11,592,278 shares of Common Stock outstanding as of November 18, 2015, as reported in the Schedule 14A, and adjusted for shares of Common Stock underlying warrants and restricted stock awards beneficially owned by Mr. Eitner and Mr. Ahern.

CUSIP No. 75955J 204				
1     Names of reporting persons				
Dr. John H. Leaman				
2				
	(a) 🗵 (	(b) 🗆		
	~ ~ ~			
3	SEC use of			
4	Source of	funds		
5	Check if o	disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) $\Box$		
6	Citizensh	ip or place of organization		
	United St	ates		
		7 Sole voting power		
		0		
		0		
		Q Charadauting news		
Nue	nber of	8 Shared voting power		
	nber of nares	0		
	ficially			
	l by each	9 Sole dispositive power		
	orting			
perse	on with	0		
		10 Shared dispositive power		
		0		
11	Aggregate	e amount beneficially owned by each reporting person		
	0			
	0			
12	Check if	the aggregate amount in Row (11) excludes certain shares		
13	Percent of	f class represented by amount in Row (11)		
	0%			
	070			
14	Type of r	enorting person		
14	14 Type of reporting person			
	IN			

CUSI	P No. 7595	55J 204	
1     Names of reporting persons			
Dr. Todd Johnson			
	<u> </u>		
2		e appropriate box if a member of a group (b) □	
	(a) 凶 (		
3	SEC use of	only	
4	Source of		
4	Source of	Tulids	
5	Check if a	disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) $\Box$	
6		ip or place of organization	
0	Chizensh	ip or place of organization	
	United St	ates	
		7 Sole voting power	
		er e	
		0	
		8 Shared voting power	
	nber of		
	nares	0	
owned	ficially 1 by each		
	orting	9 Sole dispositive power	
	on with	0	
		10 Shared dispositive power	
		0	
11	Aggregate	e amount beneficially owned by each reporting person	
	0		
	0		
10	Charle : C	the accurace to amount in Day (11) analysics contain charge $\Box$	
	12 Check if the aggregate amount in Row (11) excludes certain shares		
13	Percent of	f class represented by amount in Row (11)	
	0%		
	070		
14	Tunc of	anarting parson	
14	1 ype of re	eporting person	
	IN		

CUSIP No. 75955J 204				
1				
Benjamin H. Snedeker				
2				
	(a) 🗵 (	(b) 🗆		
3	SEC use			
4	Source of	funds		
5	Check if	disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) $\Box$		
6	Citizensh	ip or place of organization		
	United St	ates		
		7 Sole voting power		
		0		
N	1 0	8 Shared voting power		
	nber of nares	0		
	ficially			
	d by each	9 Sole dispositive power		
rep	orting			
pers	on with	0		
		10 Shared dispositive power		
		0		
11	Aggregat	e amount beneficially owned by each reporting person		
	0			
	0			
12	Check if	the aggregate amount in Row (11) excludes certain shares		
13	Percent o	f class represented by amount in Row (11)		
	0%			
	070			
14	Type of r	eporting person		
14	rype of f	cporting person		
	IN			

CUSIP No. 75955J 204				
	1     Names of reporting persons			
	David Bu	uchen		
2	Check the appropriate box if a member of a group			
		(b) □		
3	SEC use of	only		
	Source of			
4	Source of	i iuids		
5	Chaolt if	disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)		
6	Citizensh	nip or place of organization		
	Linited Ct	toton		
	United St	tates		
		7 Sole voting power		
		0		
		0		
		8 Shared voting power		
	nber of	0		
	ares ficially			
	by each	9 Sole dispositive power		
	orting	9 Sole dispositive power		
	on with	0		
		10 Shared dispositive power		
		0		
11	Aggregate	te amount beneficially owned by each reporting person		
11	116610540	to another conclusion of our reporting person		
	0			
12	12 Check if the aggregate amount in Row (11) excludes certain shares			
	<ul> <li>12 Check if the aggregate amount in Row (11) excludes certain shares 11</li> <li>13 Percent of class represented by amount in Row (11)</li> </ul>			
15	rereent 0	i class represented by amount in Kow (11)		
	0%			
	570			
14	Type of #	reporting person		
14	14 Type of reporting person			
	IN			

CUSIP No. 75955J 204						
1     Names of reporting persons						
	Timothy	imothy S. Callahan				
2 Check the appropriate box if a member of a group			ppriate box if a member of a group			
	(a) 🗵	(b) 🗆				
3	SEC use	only				
4	Source of	tunds				
5	Check if	disclos	sure of legal proceedings is required pursuant to Item $2(d)$ or $2(e)$			
6	Citizensn	ip or p	lace of organization			
	United St	ates				
		7	Sole voting power			
			0			
		8	Shared voting power			
	nber of		0			
	nares eficially		0			
	d by each	9	Sole dispositive power			
rep	orting	,				
pers	on with		0			
		10	Shared dispositive power			
			0			
11	Aggregat	e amou	ant beneficially owned by each reporting person			
	0					
12	12 Check if the aggregate amount in Row (11) excludes certain shares □					
13						
	0%					
14	Type of r	eportir	ng person			
IN						
	11N					

This Amendment No. 6 amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "<u>SEC</u>") on October 22, 2015 (the "<u>Original Schedule 13D</u>"), as amended by Amendment No. 1 filed with the SEC on November 5, 2015 (the "<u>First Amendment</u>"), Amendment No. 2 filed with the SEC on December 7, 2015 (the "<u>Second Amendment</u>"), Amendment No. 3 filed with the SEC on December 8, 2015 (the "<u>Third Amendment</u>"), Amendment No. 4 filed with the SEC on December 9, 2015 (the "<u>Fourth Amendment</u>") and Amendment No. 5 filed with the SEC on December 21, 2015 (the "<u>Fifth Amendment</u>" and together with the Original Schedule 13D, the First Amendment, the Second Amendment, the Third Amendment and the Fourth Amendment, the "<u>Schedule 13D</u>") relating to the common stock, \$0.001 par value per share (the "<u>Common Stock</u>"), of Relmada Therapeutics, Inc., a Nevada corporation (the "<u>Issuer</u>"). The address of the principal executive office of the Issuer is 757 Third Avenue, Suite 2018, New York, NY 10017.

Capitalized terms not defined herein shall have the meaning ascribed to them in the Schedule 13D. Except as set forth herein, the Schedule 13D is unmodified.

Item 2 of the Schedule 13D is hereby amended and supplemented as follows:

#### Item 2. Identity and Background.

Item 2 (d)-(e) of the Schedule 13D is hereby amended and supplemented by adding the following information:

On December 22, 2015, the Federal District Court for the District of Nevada issued, pending a full trial on the merits, a preliminary injunction enjoining Laidlaw, Matthew D. Eitner and James P. Ahern (the "<u>Defendants</u>") from disseminating false and misleading proxy materials and requiring them to retract or correct any false and misleading proxy materials in the same manner set forth in the ex parte temporary restraining order issued against the Defendants on December 10, 2015, as disclosed in the Fifth Amendment and the December 21 Press Release.

### SIGNATURES

After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 29, 2015

## LAIDLAW & COMPANY (UK) LTD.

By: <u>/s/ Matthew D. Eitner</u> Name: Matthew D. Eitner Title: Chief Executive Officer

/s/ Matthew D. Eitner

Matthew D. Eitner

Individually and as attorney-in-fact for Dr. John H. Leaman, Dr. Todd Johnson, Benjamin H. Snedeker, David Buchen and Timothy S. Callahan

/s/ James P. Ahern

James P. Ahern